Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

INTRODUCTION: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. METHODS: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran, Emine, Ozturk, Zeynep Ozge, Bilgin, Emre, Büyükaşık, Yahya, Dizdar, Omer, Yardimci, Gozde Kubra, Farisogullari, Bayram, Özsoy, Zehra, Ayan, Gizem, Uzun, Gullu Sandal, Ekici, Mustafa, Unaldi, Erdinc, Kilic, Levent, Akdoğan, Ali, Karadag, Omer, Bilgen, Şule Apraş, Kiraz, Sedat, Kalyoncu, Umut, Ertenli, Ali Ihsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326223/
https://www.ncbi.nlm.nih.gov/pubmed/37294405
http://dx.doi.org/10.1007/s40744-023-00563-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326223/
https://www.ncbi.nlm.nih.gov/pubmed/37294405
http://dx.doi.org/10.1007/s40744-023-00563-z

Ejemplares similares